Chembio Diagnostics

No. 404: Chembio’s Brazilian breakthrough, fertile ground in Commack and a West Coast cameo – plus, scampi for all!

  Weekend Avenger: Welcome to Friday, dear readers, and now that the “Endgame” spoiler ban is officially lifted, welcome back to everyone previously dusted by the Thanos Snap. You’ve survived both a universal genocide and another busy workweek – well done on both counts. Mother of all days: It’s May 10 out there, and to our readers in El Salvador, Guatemala and Mexico, a very happy Mother’s Day. Our Mother’s Day is Sunday. You still…


Chembio’s dengue field test earns Brazilian nod

By GREGORY ZELLER // Add another critical Brazilian regulatory approval to Chembio Diagnostics’ portfolio. The Medford-based point-of-care diagnostics specialist announced this its week the Agência Nacional de Vigilância Sanitária, Brazil’s federal health-regulatory agency, has approved Chembio’s DPP Dengue System. The test allows “simultaneous and discrete” detection of antibodies against all four dengue serotypes, covering both active infection by dengue virus and prior exposure to the virus – critical measures for both treatment and surveillance of…


No. 351: One world, truth in electioneering and another IPS lightbulb moment (plus: teleporting with Gil Perez!)

  Welcome to Wednesday: Over the hump of another busy workweek, dear friends. We are the world: To our readers in the 193 sovereign states comprising the U.N. General Assembly, a peaceful United Nations Day, celebrated every Oct. 24 since 1948. At a time when some would suggest that nationalism – defined as promoting national interests “to the exclusion or detriment of the interests of other nations” – is the way to go, the U.N.’s…


No. 331: A retail first at Roosevelt Field, phone calls from outer space and why dumping debris in LI waters is good (sometimes)

Hump-hopping: Welcome to Wednesday, dear readers, as we speed through another exciting (and mercilessly damp) week of socioeconomic innovation. It’s Aug. 15 out there, and today we observe the 73rd anniversary of Victory Over Japan Day. Sorta. (It could be Aug. 15, the date Japan officially announced its surrender, but it could also be Aug. 14 – the surrender date in the States, because of time zones – or possibly Sept. 2, the date Japan…


Chembio HIV-syphilis test OK’d for Europe, Caribbean

Chembio Diagnostics has been approved to sell its combination test for HIV and syphilis in most of Europe and the Caribbean. The single-use test kits offer rapid detection of antibodies to HIV types 1 and 2 and syphilis Treponema pallidum using whole blood from a finger stick, venous whole blood, serum or plasma. The test requires a tiny blood sample, provides results in as little as 15 minutes and has shelf life of up to 2 years….


In Brazil, a big forward step for Chembio

The national health-regulatory agency of Brazil has approved commercial use of Chembio Diagnostics’ rapid field rest for the Zika virus – a major step toward selling the product in the Zika-ravaged Brazilian market. Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA) has greenlighted the DPP Zika IgM/IgG Assay, which detects antibodies using a tiny drop of blood and provides “semi-quantitative results” in 15 minutes, according to the company, using Chembio Diagnostics’ patented virus-detection platform and a…


International intrigue at Medford’s Chembio

By GREGORY ZELLER // With declining Latin American sales contributing to a revenues losing streak, Chembio Diagnostics has shaken up its international rotation. The Medford-based biotech, which manufactures rapid point-of-care tests for HIV and syphilis, has had its ups and downs, and the latter have largely occurred south of the border. Reporting in March on the 2015 fiscal year, CEO John Sperzel pinned steep revenue and sales drops on a product glut in Mexico and…


Chembio lands $13.2M Zika contract

Medford-based Chembio Diagnostics has won a $13.2 million federal contract to further develop its rapid test for the Zika virus, the company announced Thursday. Almost $6 million of the money – from the Department of Health and Human Services – will go toward its Zika test and a companion field monitor, the company said. Another $7.3 million will be used for development of a combination test for Zika, chikungunya and dengue. The firm, which also makes…


Chembio misses on drop in Latin American biz

By GREGORY ZELLER // An oversupplied Latin American market put a dent in Chembio Diagnostic’s 2015 earnings, but coming battles with the Zika virus may turn fortunes around. That was the message to investors Tuesday as CEO John Sperzel III reported the Medford firm’s financials for the year ended Dec. 31, 2015. While the company’s science – point-of-care diagnostic tests for infectious diseases – is in increasing demand, the numbers were not great. Chembio’s reported…


Chembio lands $550K grant for Zika test

Chembio Diagnostics has been awarded a $550,000 “catalyst grant” to develop a rapid test for the Zika virus and similar maladies. The grant comes from Microsoft co-founder Paul G. Allen, who has a long history of supporting Chembio’s research efforts, most recently surrounding the Ebola outbreak. Company officials said Chembio will develop a test to detect Zika alone, and another to detect Zika, dengue and chikungunya viruses. The company also will add Zika to a six-virus…


Chembio lands $2.1M grant from Microsoft’s Allen

Medford-based Chembio Diagnostics has been awarded a $2.1 million grant from Microsoft co-founder Paul G. Allen to develop a speedier test for fevers, including Ebola and malaria. The one-year grant, from a $100 million Allen-funded Ebola eradication program, will cover development costs of a one-shot blood test for malaria, dengue, Ebola, Lassa, Marburg and chikungunya. Chembio chief executive John J. Sperzel said the six illnesses are characterized by a high-grade fever and can be fatal when…